{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/innovative-approaches-help-recruit-and-retain-patients-rare-disease-hematology-study#webpage",
"url": "https://www.fortrea.com/insights/innovative-approaches-help-recruit-and-retain-patients-rare-disease-hematology-study",
"name": "Innovative approaches help recruit and retain patients in a rare disease hematology study",
"description": "This Fortrea case study explores how patient retention strategies supported the successful delivery of a rare disease hematology clinical trial through decentralized and patient-centric operational approaches. Conducting Phase III hematology trial management in rare disease settings presents significant challenges related to patient burden, long-term participation, and global study coordination. The case study highlights how decentralized clinical trial solutions, remote patient monitoring clinical trials, and digital health solutions for clinical trials were implemented to improve patient engagement and retention across geographically dispersed populations. By integrating ePRO clinical trial solutions, flexible visit models, and patient-centric clinical trial design, the study reduced participation burden while maintaining high-quality data collection and protocol compliance. This Fortrea case study demonstrates how innovative retention strategies, global rare disease clinical operations, and tailored rare disease clinical trial services can improve retention and operational efficiency in complex rare disease hematology clinical trials."
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "Innovative approaches help recruit and retain patients in a rare disease hematology study",
"item": "https://www.fortrea.com/insights/innovative-approaches-help-recruit-and-retain-patients-rare-disease-hematology-study"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry—as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. This commitment is further reinforced by the launch of Fortrea Intelligent Technology, enabling smarter, more connected, and data-driven clinical development. Through Fortrea Intelligent Technology, the organization is advancing data-driven, technology-enabled clinical development to improve speed, quality, and patient outcomes. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/innovative-approaches-help-recruit-and-retain-patients-rare-disease-hematology-study#casestudy",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/innovative-approaches-help-recruit-and-retain-patients-rare-disease-hematology-study#webpage"
},
"headline": "Patient Retention in Rare Disease Hematology Clinical Trials | Fortrea Case Study",
"description": "This Fortrea case study explores how patient retention strategies supported the successful delivery of a rare disease hematology clinical trial through decentralized and patient-centric operational approaches. Conducting Phase III hematology trial management in rare disease settings presents significant challenges related to patient burden, long-term participation, and global study coordination. The case study highlights how decentralized clinical trial solutions, remote patient monitoring clinical trials, and digital health solutions for clinical trials were implemented to improve patient engagement and retention across geographically dispersed populations. By integrating ePRO clinical trial solutions, flexible visit models, and patient-centric clinical trial design, the study reduced participation burden while maintaining high-quality data collection and protocol compliance. This Fortrea case study demonstrates how innovative retention strategies, global rare disease clinical operations, and tailored rare disease clinical trial services can improve retention and operational efficiency in complex rare disease hematology clinical trials.",
"genre": "Case Study",
"image": {
"@type": "ImageObject",
"url": "https://www.fortrea.com/sites/default/files/2025-02/retain-patients-in-a-rare-disease-hematology-study_0.jpg"
},
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2025-02-04",
"dateModified": "2025-02-04",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2025-02/retain-patients-in-a-rare-disease-hematology-study.pdf",
"encodingFormat": "application/pdf"
}
}
]
}